---
search:
  boost: 2 
---

# Diabetes – Insulin

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                                 | Generic Name                                                            | Quantity | Time (Days) |
| :---------------------------------------- | :---------------------------------------------------------------------- | :------: | :---------: |
| Apidra                                    |                                                                         |          |             |
| Humalog 50-50                             |                                                                         |          |             |
| Humalog 75-25                             |                                                                         |          |             |
| Humalog U-100 <sup>QL</sup>               | Insulin Lispro Soln Subcutaneous Inj 100 Unit / ML (all formulations)   |   306    |     102     |
| Humulin 70-30                             |                                                                         |          |             |
| Humulin R U-500 <sup>QL</sup>             | Insulin Regular Soln Subcutaneous Inj 500 Unit / ML (all formulations)  |   61.2   |     102     |
| Insulin Aspart <sup>QL</sup>              | Insulin Aspart Soln Subcutaneous Inj 100 Unit / ML (all formulations)   |   306    |     102     |
| Insulin Aspart Protamine / Insulin Aspart |                                                                         |          |             |
| Insulin Lispro <sup>QL</sup>              | Insulin Lispro Soln Subcutaneous Inj 100 Unit / ML (all formulations)   |   306    |     102     |
| Lantus <sup>BvG QL</sup>                  | Insulin Glargine Soln Subcutaneous Inj 100 Unit / ML (all formulations) |   204    |     102     |
| Levemir                                   |                                                                         |          |             |
| Novolog 70-30                             |                                                                         |          |             |
| Novolog U-100 <sup>QL</sup>               |                                                                         |          |             |
| Toujeo                                    |                                                                         |          |             |
| Tresiba <sup>ST</sup>                     |                                                                         |          |             |

### Non-Preferred

| Non-Preferred                  | Generic Name                                                            |         Quantity          |        Time (Days)        |
| :----------------------------- | :---------------------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Admelog <sup>QL</sup>          | Insulin Lispro Soln Subcutaneous Inj 100 Unit / ML (all formulations)   | Determined pursuant to PA | Determined pursuant to PA |
| Afrezza                        |                                                                         |                           |                           |
| Basaglar <sup>QL</sup>         | Insulin Glargine Soln Subcutaneous Inj 100 Unit / ML (all formulations) | Determined pursuant to PA | Determined pursuant to PA |
| Fiasp <sup>QL</sup>            | Insulin Aspart Soln Subcutaneous Inj 100 Unit / ML (all formulations)   | Determined pursuant to PA | Determined pursuant to PA |
| Humalog U-200 <sup>QL</sup>    | Insulin Lispro Soln Subcutaneous Inj 200 Unit / ML (all formulations)   | Determined pursuant to PA | Determined purusant to PA |
| Humulin N U-100                |                                                                         |                           |                           |
| Humulin R U-100                |                                                                         |                           |                           |
| Insulin Glargine <sup>QL</sup> | Insulin Glargine Soln Subcutaneous Inj 100 Unit / ML (all formulations) | Determined pursuant to PA | Determined pursuant to PA |
| Lyumjev                        |                                                                         |                           |                           |
| Novolin 70-30                  |                                                                         |                           |                           |
| Novolin N U-100                |                                                                         |                           |                           |
| Novolin R U-100                |                                                                         |                           |                           |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Step Therapy Criteria

- Must have had an inadequate clinical response of at least **120 days** with at least **one
preferred** drug having a similar duration of action 

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **120 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Inhaled Insulin (Afrezza)

Additional Inhaled Insulin (Afrezza) Criteria

- Must provide documentation of spirometry testing prior to initiation with a predicted FEV1 ≥70% - Will not be authorized for patients with asthma or COPD
- Must provide documentation of being nicotine-free for at least 180 days

## Additional Information

- An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.
- Requests may be authorized for patients with a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=53)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=20)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
